home / stock / awkn:cc / awkn:cc news

AWKN:CC News and Press, AWAKN LIFE SCIENCES CORP. From 05/05/22

Stock Information
Company Name: AWAKN LIFE SCIENCES CORP.
Stock Symbol: AWKN:CC
Market: AQNC
Website: awaknlifesciences.com
Menu
AWKN:CC AWKN:CC Quote AWKN:CC Short AWKN:CC News AWKN:CC Articles AWKN:CC Message Board
Get AWKN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AWKN:CC - Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Toronto, Ontario--(Newsfile Corp. - May 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, announced today that Awakn's management team is scheduled to ...
AWKN:CC - KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing

NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27 th and 28 th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing....

AWKN:CC - Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results

Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, today is reporting its financial results and business ...

AWKN:CC - Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Toronto, Ontario--(Newsfile Corp. - April 13, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, today is providing shareholders with a business updat...
AWKN:CC - Awakn Successfully Completes Phase One of Its Drug Discovery Program

Two Chemical Series Identified to Facilitate Lead Optimisation Activities Toronto, Ontario--(Newsfile Corp. - April 6, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering revolutionary therapeutics...

AWKN:CC - Awakn Life Sciences to Participate in Upcoming April 2022 Conferences

Toronto, Canada--(Newsfile Corp. - April 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Awakn's Chief Execu...

AWKN:CC - Awakn Life Sciences Announces Closing of Private Placement

Toronto, Ontario--(Newsfile Corp. - March 22, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (" Awakn " or the " Company "), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, is pleased to announce that they ha...
AWKN:CC - Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

London Clinic Will Begin Delivering Ketamine-Assisted Therapy for Addiction & Mental Health Third Location Adds to Two Existing Operatons in Bristol and Oslo Toronto, Ontario--(Newsfile Corp. - March 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), ...

AWKN:CC - Awakn Life Sciences Appoints Kevin Lorenz as U.S. Head of Commercial Development

Brings Over 20 Years of Commercial Biotech Experience to Lead Awakn's Therapeutics Commercialization Activities in the U.S. Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, de...

AWKN:CC - Awakn Life Sciences to Participate at Upcoming March 2022 Conferences

Toronto, Ontario--(Newsfile Corp. - March 9, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Awakn's Chief Exec...
Previous 10 Next 10